Newer generation ALKIs, such as ceritinib, alectinib, ensartinib, and brigatinib, exhibit a different spectrum of ALK resistance mutations; these newer generation ALKIs have been indicated for NSCLC patients who fail treatment with crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.